Role of autologous stem cell transplantation in multiple myeloma.

abstract：PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...

journal_title：Current hematologic malignancy reports

authors： Torka P,Barth M,Ferdman R,Hernandez-Ilizaliturri FJ

更新日期：2019-10-01 00:00:00

abstract：:Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...

journal_title：Current hematologic malignancy reports

authors： Raza S,Leng S,Lentzsch S

更新日期：2017-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...

journal_title：Current hematologic malignancy reports

authors： Kennedy JA,Hobbs G

更新日期：2018-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...

journal_title：Current hematologic malignancy reports

authors： Choi Y,Diefenbach CS

更新日期：2020-04-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...

journal_title：Current hematologic malignancy reports

authors： Gergis U,Wissa U

更新日期：2010-01-01 00:00:00

abstract：PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...

journal_title：Current hematologic malignancy reports

authors： Hilal T,Munoz J

更新日期：2020-08-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a complex clonal disorder. The disease is characterized by chromosomal and molecular abnormalities that propagate and expand the abnormal clone(s). The main goal of therapy is to achieve and ultimately maintain a complete remission. In the younger AML patient (less than 60 years of age)...

journal_title：Current hematologic malignancy reports

authors： Fernandez HF

更新日期：2016-10-01 00:00:00

abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...

journal_title：Current hematologic malignancy reports

authors： La Rosée P,Hochhaus A

更新日期：2008-04-01 00:00:00

abstract：:Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

journal_title：Current hematologic malignancy reports

authors： Karp Leaf R,Cho HJ,Avigan D

更新日期：2015-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...

journal_title：Current hematologic malignancy reports

authors： Bradley TJ,Watts JM,Swords RT

更新日期：2018-12-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and ...

journal_title：Current hematologic malignancy reports

authors： Cull EH,Altman JK

更新日期：2014-06-01 00:00:00

abstract：PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...

journal_title：Current hematologic malignancy reports

authors： Ertz-Archambault N,Khera N

更新日期：2020-10-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...

journal_title：Current hematologic malignancy reports

authors： Kahl BS

更新日期：2009-10-01 00:00:00

abstract：:The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

journal_title：Current hematologic malignancy reports

authors： Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

更新日期：2012-09-01 00:00:00

abstract：:The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...

journal_title：Current hematologic malignancy reports

authors： Pemmaraju N,Gupta V,Mesa R,Thompson MA

更新日期：2015-12-01 00:00:00

abstract：:In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and in...

journal_title：Current hematologic malignancy reports

authors： Guglielmelli T,Palumbo A

更新日期：2013-12-01 00:00:00

abstract：PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

journal_title：Current hematologic malignancy reports

authors： Hakki M

更新日期：2020-04-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...

journal_title：Current hematologic malignancy reports

authors： Lekakis LJ,Cooper BW,de Lima MG

更新日期：2014-06-01 00:00:00

abstract：:The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...

journal_title：Current hematologic malignancy reports

authors： Zappasodi R,Wolchok JD,Merghoub T

更新日期：2019-02-01 00:00:00

abstract：PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

journal_title：Current hematologic malignancy reports

authors： Patel AA,Odenike O

更新日期：2020-12-01 00:00:00

abstract：:No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...

journal_title：Current hematologic malignancy reports

authors： Gertz MA,Zeldenrust SR

更新日期：2009-04-01 00:00:00

abstract：:Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...

journal_title：Current hematologic malignancy reports

authors： Zinzani PL

更新日期：2011-12-01 00:00:00

abstract：:In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...

journal_title：Current hematologic malignancy reports

authors： Campana D

更新日期：2008-07-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...

journal_title：Current hematologic malignancy reports

authors： Sirulnik LA,Stone RM

更新日期：2008-01-01 00:00:00

abstract：:Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

journal_title：Current hematologic malignancy reports

authors： Chung CG,Poligone B

更新日期：2015-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...

journal_title：Current hematologic malignancy reports

authors： Bangerter LR,Griffin JM,Langer S,Hasan B,Kim WS,Murad MH,Khera N

更新日期：2018-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...

journal_title：Current hematologic malignancy reports

authors： Khoury JD

更新日期：2018-12-01 00:00:00

abstract：:Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

journal_title：Current hematologic malignancy reports

authors： Buckley SA,Walter RB

更新日期：2015-06-01 00:00:00

abstract：PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...

journal_title：Current hematologic malignancy reports

authors： Darrah JM,Herrera AF

更新日期：2018-10-01 00:00:00

abstract：:BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...

journal_title：Current hematologic malignancy reports

authors： Scherber RM,Geyer HL,Mesa RA

更新日期：2014-12-01 00:00:00